Cormedix Inc. (CRMD)
NASDAQ:CRMD
Want to see CRMD full AI Analyst Report?
CRMD Stock Chart & Stats
$7.39
$0.06(0.58%)
At close: 4:00 PM EST
$7.39
$0.06(0.58%)
Day’s Range― - ―
52-Week Range$6.13 - $17.43
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.27M
Market Cap
$662.13M
Enterprise Value$628.93M
Total Cash (Recent Filing)$178.09M
Total Debt (Recent Filing)$144.88M
Price to Earnings (P/E)3.7
Beta1.58
Next Earnings
Aug 06, 2026EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.38
Shares Outstanding78,451,890
10 Day Avg. Volume1,494,071
30 Day Avg. Volume1,274,131
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.07
Price to Sales (P/S)2.69
P/FCF Ratio4.85
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit1.83
Enterprise Value/Ebitda2.85
Forecast
1Y Price Target
$14.25Price Target Upside92.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.57
Revenue Forecast (FY)$334.52M
Bulls Say, Bears Say
Bulls Say
Cash GenerationStrong TTM operating and free cash flow (~$198M/$197M) with FCF roughly matching net income and $178.1M ending cash gives durable internal financing for commercial expansion, share repurchases, and R&D, reducing reliance on external capital if recent performance sustains.
DefenCath AdoptionDefenCath’s large Q1 sales ($97.5M) and reported durable utilization increases with major dialysis providers signal entrenched clinical adoption. As a recurring catheter-lock therapy, this supports predictable unit demand and recurring revenue, underpinning longer-term commercial growth.
Pipeline DiversificationPositive Phase III ReSPECT results and planned sNDA (H2 2026) with potential 2027 launch materially broaden CorMedix’s portfolio beyond DefenCath. Rezafungin’s prophylaxis positioning in hospitals can diversify institutional revenue and reduce single-product dependence over time.
Bears Say
Reimbursement RiskTDAPA expiration and the CMS transition to a post‑TDAPA add‑on methodology create structural reimbursement uncertainty. Anticipated price erosion and timing variability in H2 2026 can materially affect unit economics, volumes and cash generation until new payment mechanisms stabilize.
Rising LeverageThe company moved from very low debt (2021–2024) to meaningful leverage (debt ~$145M vs equity ~$437M). This material increase reduces financial flexibility, raises refinancing and interest rate exposure, and heightens downside risk if recent profitability normalizes.
Revenue Concentration & VariabilityRevenue concentration in DefenCath together with one-off timing items (a $9M favorable Q1 adjustment and an expected Q2 shelf‑stock cadence) amplifies top‑line volatility. Combined with prior years of losses, this concentration raises the risk of revenue and margin reversals.
Cormedix News
CRMD FAQ
What was Cormedix Inc.’s price range in the past 12 months?
Cormedix Inc. lowest stock price was $6.13 and its highest was $17.43 in the past 12 months.
What is Cormedix Inc.’s market cap?
Cormedix Inc.’s market cap is $662.13M.
When is Cormedix Inc.’s upcoming earnings report date?
Cormedix Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 65 days.
How were Cormedix Inc.’s earnings last quarter?
Cormedix Inc. released its earnings results on May 14, 2026. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.343 by $0.087.
Is Cormedix Inc. overvalued?
According to Wall Street analysts Cormedix Inc.’s price is currently Undervalued.
Does Cormedix Inc. pay dividends?
Cormedix Inc. does not currently pay dividends.
What is Cormedix Inc.’s EPS estimate?
Cormedix Inc.’s EPS estimate is 0.24.
How many shares outstanding does Cormedix Inc. have?
Cormedix Inc. has 78,451,890 shares outstanding.
What happened to Cormedix Inc.’s price movement after its last earnings report?
Cormedix Inc. reported an EPS of $0.43 in its last earnings report, beating expectations of $0.343. Following the earnings report the stock price went up 5.733%.
Which hedge fund is a major shareholder of Cormedix Inc.?
Currently, no hedge funds are holding shares in CRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cormedix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.25 (92.83% Upside)
$14.25 (92.83% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 327.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.93%
12-Months-Change
Fundamentals
Return on Equity
50.38%
Trailing 12-Months
Asset Growth
445.27%
Trailing 12-Months
Company Description
Cormedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CRMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: large Q1 revenue and adjusted EBITDA beats, raised full‑year guidance, successful REZZAYO Phase III top‑line results with near‑term regulatory path, and solid cash generation. Offsetting risks include near‑term reimbursement variability from TDAPA expiry affecting H2 2026, a nonrecurring $9M revenue adjustment, mark‑to‑market charges, and a delayed TPN Phase III timeline pushing that program into 2028. On balance the positive execution, guidance increases, pipeline progress (REZZAYO) and strong balance sheet outweigh the highlighted challenges.View all CRMD earnings summariesCRMD Stock 12 Month Forecast
Average Price Target
$14.25
▲(92.83% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―
Ownership Overview
2.91% Insiders
10.35% Mutual Funds
17.83% Other Institutional Investors
55.74% Public Companies and Individual Investors